C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
6.45
+0.84 (14.97%)
At close: Nov 4, 2024, 4:00 PM
6.31
-0.14 (-2.17%)
After-hours: Nov 4, 2024, 7:38 PM EST
C4 Therapeutics Employees
C4 Therapeutics had 145 employees as of December 31, 2023. The number of employees decreased by 1 or -0.68% compared to the previous year.
Employees
145
Change (1Y)
-1
Growth (1Y)
-0.68%
Revenue / Employee
$232,193
Profits / Employee
-$727,566
Market Cap
455.30M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 145 | -1 | -0.68% |
Dec 31, 2022 | 146 | 25 | 20.66% |
Dec 31, 2021 | 121 | 22 | 22.22% |
Dec 31, 2020 | 99 | 11 | 12.50% |
Dec 31, 2019 | 88 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Cross Country Healthcare | 13,131 |
ZimVie | 2,600 |
Sangamo Therapeutics | 405 |
Amylyx Pharmaceuticals | 384 |
AirSculpt Technologies | 381 |
Esperion Therapeutics | 240 |
Voyager Therapeutics | 162 |
ProQR Therapeutics | 157 |
CCCC News
- 7 days ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - GlobeNewsWire
- 26 days ago - C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 2 months ago - C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 3 months ago - C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire